Fact CheckerSign in

NCT06338956Completed

Optimal Attained LDL-Cholesterol Levels in Patients Who Achieved ≥50% LDL Reduction After PCI

Source: ClinicalTrials.gov · Last updated 21 May 2025

Brief summary (registry, in English)

For the management of low-density lipoprotein-cholesterol (LDL-C), some guidelines recommend initial statin treatment with high-intensity statins to achieve at least a 50% reduction in LDL-C levels. High-intensity or maximally tolerated intensity can be maintained without a target goal. However, the European guideline recommends less than 55 mg/dL of LDL-C after PCI.

Status (registry)
Completed
Study type
Observational
Enrollment
135877 (actual)
First submitted
24 Mar 2024
Start date
1 Jan 2024
Primary completion date
31 Dec 2024
Lead sponsor
Samsung Medical Center
NCT number
NCT06338956

What you commit to

  • Study type: Observational
  • Participants enrolled: 135877
  • From 1 Jan 2024 to the primary completion date, 31 Dec 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients receiving statin before PCI

Other illness

  • Patients with cancer

Lab values

  • Patients with LDL-C \<55 mg/dL before PCI

Other

  • Patients with liver cirrhosis
  • Patients without prescription of statin

Who the study is looking for

  • Patients receiving PCI with health check up before and after PCI within 3 years

Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Samsung Medical Center
Coordinator of this site? Confirm its status
SeoulSouth KoreaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.